It’s SCD GDM role and potential utility as a therapeutic target for SCD was only discovered by genome-wide association studies (GWAS), linking BCL11A mutations to elevated γ-globin levels and, thus, by inference to milder SCD-related VOC and pain phenotypes [10]. This evidence concerns the gene BCL11A and Schnyder corneal dystrophy.